
News|Slideshows|August 4, 2021
Diabetes Drugs and Cardioprotection: A Summary for Primary Care
Author(s)Leo Robert
These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.
Advertisement
Recent study findings—many of which were presented at the recent American Diabetes Association (ADA) 81st Scientific Sessions—have demonstrated cardioprotective effects of sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). In the slides below, find concise summaries of the more significant developments in the use of diabetes drugs for ASCVD prevention.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
2
Why Prostate Cancer Screening Belongs in Primary Care
3
FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD
4
Migraine, Estrogen, and Pregnancy Shape Stroke Risk in Women
5























































































































































